Tag: Vyome Bioscience
Vyome reports positive final phase 2 results for VT-1953; Plans to...
Based on these positive Phase 2 results, the company plans to advance VT-1953 into a pivotal study following discussions with the FDA to seek approval to enter $1B potential addressable market opportunity
Vyome Therapeutics begins phase 2 trial of its drug for acne...
The company has dosed the first patient in its Phase 2 trial of the Company’s lead clinical candidate, VB-1953, for the treatment of moderate to severe inflammatory acne vulgaris......................
Eyeing big dermatology market, Vyome Biosciences raises $14 million fresh funding
As a result of funding, the company's lead program VB 1953, targeting the large unmet need of antibiotic-resistant acne is expected to.....